Management of Chronic Viral Hepatitis B and D

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2024 Jun 14

PMID 38872774

Authors

Christopher Dietz-Fricke

Heiner Wedemeyer

Affiliations

Soon will be listed here.

References

Degasperi E, Anolli M, Lampertico P . Bulevirtide-based treatment strategies for chronic hepatitis delta: A review. J Viral Hepat. 2023; 30 Suppl 1:26-32. DOI: 10.1111/jvh.13811. View

Dietz-Fricke C, Tacke F, Zollner C, Demir M, Schmidt H, Schramm C . Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. JHEP Rep. 2023; 5(4):100686. PMC: 10071092. DOI: 10.1016/j.jhepr.2023.100686. View

Sandmann L, Degasperi E, Port K, Aleman S, Wallin J, Manuilov D . Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection. Aliment Pharmacol Ther. 2024; 59(6):752-761. DOI: 10.1111/apt.17878. View

Hughes S, Wedemeyer H, Harrison P . Hepatitis delta virus. Lancet. 2011; 378(9785):73-85. DOI: 10.1016/S0140-6736(10)61931-9. View

Dietz-Fricke C, Degasperi E, Jachs M, Maasoumy B, Reiter F, Geier A . Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series. Hepatology. 2024; 80(3):664-673. PMC: 11332372. DOI: 10.1097/HEP.0000000000000847. View

Trepo C, Chan H, Lok A . Hepatitis B virus infection. Lancet. 2014; 384(9959):2053-63. DOI: 10.1016/S0140-6736(14)60220-8. View

Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, De Franchis R . A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009; 136(5):1629-38. DOI: 10.1053/j.gastro.2009.01.052. View

Chen H, Chang M, Ni Y, Hsu H, Lee P, Lee C . Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA. 1996; 276(11):906-8. View

Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M . Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336(26):1855-9. DOI: 10.1056/NEJM199706263362602. View

10.

Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T . . Z Gastroenterol. 2021; 59(7):691-776. DOI: 10.1055/a-1498-2512. View

11.

Jachs M, Panzer M, Hartl L, Schwarz M, Balcar L, Camp J . Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression. JHEP Rep. 2023; 5(8):100751. PMC: 10285645. DOI: 10.1016/j.jhepr.2023.100751. View

12.

Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P . A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. N Engl J Med. 2023; 389(1):22-32. DOI: 10.1056/NEJMoa2213429. View

13.

. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022; 7(9):796-829. PMC: 9349325. DOI: 10.1016/S2468-1253(22)00124-8. View

14.

Stockdale A, Kreuels B, Henrion M, Giorgi E, Kyomuhangi I, de Martel C . The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020; 73(3):523-532. PMC: 7438974. DOI: 10.1016/j.jhep.2020.04.008. View

15.

. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023; 79(2):433-460. DOI: 10.1016/j.jhep.2023.05.001. View